Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Long-Term Debt Repayments (2016 - 2019)

Historic Long-Term Debt Repayments for BioRestorative Therapies (BRTX) over the last 9 years, with Q3 2019 value amounting to $1.3 million.

  • BioRestorative Therapies' Long-Term Debt Repayments rose 56040.19% to $1.3 million in Q3 2019 from the same period last year, while for Sep 2019 it was $4.0 million, marking a year-over-year increase of 61305.28%. This contributed to the annual value of $863302.0 for FY2018, which is 16146.72% up from last year.
  • BioRestorative Therapies' Long-Term Debt Repayments amounted to $1.3 million in Q3 2019, which was up 56040.19% from $886629.0 recorded in Q2 2019.
  • BioRestorative Therapies' 5-year Long-Term Debt Repayments high stood at $1.3 million for Q3 2019, and its period low was -$4500.0 during Q3 2017.
  • Its 5-year average for Long-Term Debt Repayments is $372198.7, with a median of $119583.0 in 2018.
  • In the last 5 years, BioRestorative Therapies' Long-Term Debt Repayments plummeted by 2850.24% in 2017 and then skyrocketed by 459213.33% in 2018.
  • BioRestorative Therapies' Long-Term Debt Repayments (Quarter) stood at $5000.0 in 2015, then soared by 790.0% to $44500.0 in 2016, then skyrocketed by 385.79% to $216176.0 in 2017, then surged by 136.72% to $511731.0 in 2018, then soared by 160.87% to $1.3 million in 2019.
  • Its Long-Term Debt Repayments stands at $1.3 million for Q3 2019, versus $886629.0 for Q2 2019 and $1.3 million for Q1 2019.